Product image of Ivabradine Chemo Ibérica (Ivabradine) supplied by GNH India

Ivabradine Chemo Ibérica

Active Ingredient:
Ivabradine
Origin:
EU

Ivabradine Chemo Ibérica (Ivabradine)

Ivabradine, the active ingredient in Ivabradine Chemo Ibérica, is a If channel inhibitor presented as an oral dosage form for oral use. It reduces heart rate and is used to treat chronic stable angina and heart failure with reduced ejection fraction in adult patients.
GNH India supplies Ivabradine Chemo Ibérica as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Chemo Ibérica, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Ivabradine acts on the cardiac If current to lower heart rate in conditions where rate control improves outcomes.
  • Chronic stable angina: reduces the frequency of angina attacks by lowering myocardial oxygen demand.
  • Heart failure with reduced ejection fraction: improves symptoms and reduces hospitalisations by decreasing heart rate.
  • Coronary artery disease requiring heart‑rate reduction: helps control heart rate when beta‑blockers are unsuitable.

How It Works

  • Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which slows the spontaneous depolarisation of pacemaker cells. This leads to a reduction in resting heart rate without affecting myocardial contractility, ventricular repolarisation, or blood pressure, thereby decreasing cardiac oxygen consumption.

Side Effects

Ivabradine may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects

  • Bradycardia: heart rate slower than intended.
  • Visual disturbances (phosphenes): transient luminous phenomena.
  • Headache.
  • Dizziness.
  • Fatigue.
  • Blurred vision.

Serious or Rare Side Effects

  • Symptomatic bradycardia requiring medical attention.
  • Atrial fibrillation or other significant arrhythmias.
  • Severe hypotension.
  • Persistent visual impairment.
  • Acute coronary syndrome in rare cases.
  • Allergic reactions such as rash or angioedema.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety aspects.

  • Cardiac monitoring: obtain baseline ECG and heart‑rate assessment.
  • Bradycardia risk: avoid use in patients with resting heart rate below 60 bpm.
  • CYP3A4 inhibitors: adjust dose or monitor when co‑administered with strong inhibitors.
  • Hepatic impairment: use with caution in moderate to severe liver disease.
  • Pregnancy and lactation: safety not established; avoid unless clearly needed.
  • Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Ivabradine can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase plasma levels.
  • Concurrent strong bradycardic agents (e.g., beta‑blockers, digoxin): risk of excessive heart‑rate reduction.
  • Other If‑channel inhibitors (e.g., ranolazine): additive effect on heart rate.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment.
  • Drugs affecting AV‑node conduction (e.g., calcium‑channel blockers): monitor ECG and heart rate.
  • Antihypertensives: may enhance hypotensive effect, requiring blood‑pressure monitoring.

Frequently Asked Questions

Ivabradine Chemo Ibérica is prescribed to lower heart rate in adults with chronic stable angina and in patients with heart failure with reduced ejection fraction. By reducing the rate at which the heart beats, it helps relieve angina symptoms and improves functional capacity in heart‑failure patients.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. This inhibition slows the spontaneous electrical activity, lowering resting heart rate without affecting the strength of cardiac contraction or blood pressure, thereby decreasing myocardial oxygen demand.

The exact dose is determined by the prescribing clinician based on the patient’s condition, heart‑rate target, and tolerance. Typical regimens start with a low dose that may be titrated upward, but the final regimen must be individualized and documented by the healthcare professional.

Safety data for Ivabradine during pregnancy and lactation are limited, and the product is classified as having an unknown risk. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for heart‑rate reduction is beta‑blockers. Unlike beta‑blockers, Ivabradine lowers heart rate without affecting myocardial contractility or blood pressure, making it useful when beta‑blockers are contraindicated or not tolerated. However, beta‑blockers also provide anti‑arrhythmic and anti‑ischemic benefits that Ivabradine does not.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging to protect from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Ivabradine Chemo Ibérica is taken orally, usually with a glass of water. It can be taken with or without food, but consistency in relation to meals is recommended to maintain stable absorption. The tablet should be swallowed whole and not crushed or chewed.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and persistent visual disturbances. Patients should report any episodes of fainting, rapid or irregular heartbeats, marked drops in blood pressure, or lasting changes in vision to their healthcare provider promptly.

Ivabradine is contraindicated in patients with a resting heart rate below 60 bpm, severe hypotension, acute decompensated heart failure, sick sinus syndrome, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of the excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ivabradine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT